Index

A

abscess 4, 21, 150, 156, 168, 192, 215
accessory breast 12, 210
adeno-myoepithelioma 21
adenocarcinoma 160
adenolipoma *see* fibroadenolipoma
adenoma 20, 21
  see also fibroadenoma
adenosis 9, 18 – 19, 213
  blunt duct 18, 19
  microglandular 19
  sclerosing 9, 19, 28, 199, 201, 214
adjuvant therapy 50 – 51
  chemotherapy 50 – 51
  hormonal therapy 51
  palliative therapy 51 – 52
aging, as risk factor 42
amastia 12
ampullae 6, 7
angiosarcoma 160
anisomastia 12
antiscatter grid 69 – 70
arteries 10, 185
asymmetry 184 – 185, 191, 210 – 212
  accessory breast 210
  asymmetric densities 128, 185
athelia 12
atheroma 157
atypical ductal hyperplasia (ADH) 18
automatic exposure control (AEC) 80 – 83, 100
average glandular dose (AGD) 66, 67, 68, 92
axillary node dissection 45, 46, 49, 219
axillary view 121

B

basement membrane 7
biopsy 172 – 174, 240 – 241
  core-needle biopsy 132 – 137, 219
  excisional biopsy 219 – 222
  radiology support 142 – 146
    preoperative localization (marking) 142 – 145
    specimen radiography 145 – 146
  sentinal node biopsy 46, 253
bisphosphonates 53, 253
blood vessels 10 – 11
  asymmetry 185
bone metastases 52, 53, 253
bra syndrome 213
breast augmentation 225 – 232
  see also breast implants
breast cancer 3
  familial/hereditary 50
  in older women 54
  invasive 25 – 31, 33
  male breast cancer 252 – 253, 254
  multicentricity 33
  multifocality 33
  noninvasive 22 – 25
  pregnancy and 34 – 35
  staging 45
  see also carcinoma; *specific types of breast cancer*
breast conservation therapy 45 – 49, 219 – 224
  contraindications for 46
  familial/hereditary breast cancer 50
  radiotherapy in 46 – 49
  recurrence after 34, 47, 49
  surgical aspects 46
breast examination 99
breast implants 149, 174 – 175, 176
  complications 227 – 230
  encapsulation 227, 228
  leakage 227, 228, 230, 231
  mammography and 121, 230
  rupture of 172, 175 – 176, 229, 230 – 232
  sweating 175
  types of 225 – 227
breast reconstruction 219
breast reduction 225
breast team 54
Bucky factor (B) 70, 92

C

C-sign 175
calcifications 185, 188, 191, 199 – 208, 219, 224, 256
  adenosis 19, 199, 201
  analysis of 199 – 200
  benign 200 – 207
  biopsy and 134
  cysts 17, 188, 224
  ductal carcinoma in situ 23 – 24, 172, 207
  fat necrosis 22, 190, 192, 200, 222
  fibroadenoma 20, 156, 188, 189, 197, 200
  granular 199 – 200, 207
  inflammatory carcinoma of the breast 33
  invasive ductal carcinoma 25 – 27
  invasive lobular carcinoma 28
  involutional 199
  lymph nodes 217
  magnification mammography 128 – 129
  malignant 207 – 208
  microcalcification detection 64, 73, 76, 89, 91, 146, 149
  MRI 175, 177
  Paget disease 32
  papilloma 190, 200
  plasma cell mastitis 22, 200
  scar 19, 222, 224
  secretory 199, 200
  sonography 167, 168
carcinoma 150, 158 – 160, 175, 189 – 190
  bilateral occurrence 33 – 34
  growth rate 35
  in situ (CIS) 22, 31, 207
    see also ductal carcinoma in situ; lobular carcinoma in situ
  inflammatory 4, 33, 51, 215
  interval cancer 36, 245 – 249
  intracystic 31 – 32, 149, 155, 189
  invasive ductal (IDC) 25 – 27, 28, 159, 214, 224, 252
  invasive lobular (ILC) 27 – 28, 160, 191, 195, 211, 214, 215, 252
  mammographically occult cancers 36, 194 – 197, 215, 239
  medullary 29 – 30, 175, 188, 189
  missed 35, 191
  mucinous (colloid) 31, 187, 189
  nipple discharge and 147 – 148
  papillary, intraductal 31, 175
  recurrence 34, 47, 49, 150, 224 – 225
  scirrhous 159
  sonography 158 – 160
  tubular 28 – 29, 175, 212, 214
  see also breast cancer
caudocranial view 121
characteristic curve 71
chemotherapy 50 – 51, 54, 253
  palliative therapy 51, 53
Cleopatra view 101, 120
compression 69, 100, 122, 154, 256, 257
  breast implants and 121, 230
  craniocaudal (CC) view 101 – 103
  lateromedial view 118
  localization of lesion 144
  mediolateral oblique (MLO) view 109 – 111
  mediolateral view 117
  MR mammography 170
  spot compression 119, 126
computed tomography (CT) 149 – 150, 230
connective tissue 6, 9, 12
contrast 61, 62, 64 – 70, 74 – 76, 80
  contrast improvement factor (C) 70
  film contrast 75 – 76
  subject contrast 74, 75
Cooper ligaments 9, 153
core-needle biopsy 132 – 137
  large-core biopsy vacuum-assisted device 137
craniocaudal (CC) view 101 – 108
  extended CC view (Cleopatra view) 120
cuboid epithelial cells 7
cyst hemangioma 12
cystosarcoma phyllodes *see* phyllodes tumor

cysts 3, 16 – 17, 19, 44, 147 – 149, 175, 186, 188, 210
diagnostic puncture 130
intracystic carcinoma 31 – 32, 149, 155, 189
intracystic papilloma 190
macrocysts 16 – 17, 224
microcysts 17, 188, 224
oil cysts 155, 190, 191 – 192, 222, 224
retention cyst 215
sonography 155 – 156, 158, 162, 188, 230
tension cysts 17, 188

D

desmoplastic reaction 193, 213
diagnostic work-up 54
diaphanoscopy 180
digital image receptors 85 – 90
digital detectors 86 – 89
image processing 90
Doppler sonography 160 – 162
dose 66, 68 – 69, 92
average glandular dose (AGD) 66, 67, 68, 92
system dose 68 – 69, 92
drill needles 132
duct ectasia 3, 19, 22
ductal carcinoma in situ (DCIS) 18, 22 – 24, 147, 189, 207, 224
intermediately differentiated 24
MRI 170, 172, 175
poorly differentiated 23
treatment 53 – 54
well differentiated 23 – 24
ductal configuration 200

E

edema 3, 4, 33, 215
side effects of therapy 49, 220 – 222, 224
elastosis 213
embryology 12
epidemiology 40 – 41
see also risk factors
epitheliosis 18, 19
estrogen dominance 42 – 43

F

familial breast cancer 50
fasciae 6, 9
fat necrosis 22, 175, 194, 213, 214, 219, 222
calcifications 192, 200, 222
oil cyst 190
fibroadenolipoma (FAL) 9, 21, 157, 188, 190, 210
fibroadenoma 3, 20, 44, 156, 188 – 189, 197, 210
calcifications 20, 156, 188, 189, 197, 200
CT 150
fine-needle aspiration 131
hyalinized 191, 194, 214
juvenile (giant) 21, 156 – 157, 167, 188, 189
MRI 172, 174, 175, 177
sonography 160, 163
fibrocystic disease 9, 16, 148, 150, 191
fibroma 12
fibrosis 213, 219, 222, 224, 228
figure of merit (FOM) 66
film 71 – 73, 256 – 257
contrast 75 – 76
processing 72 – 73, 98
speed 71 – 72, 73
fine-needle aspiration (FNA) 130 – 132, 162
foreign body reaction 222, 227, 230

G

galactocele 155 – 156, 167, 191
galactography 147 – 148
galactorrhea 3, 22
genetic predisposition 42
glandular tissue 6, 184, 186, 209
asymmetry 184 – 185
granuloma 175, 230
guide wires 142 – 144
gynecomastia 252, 254

H

halo 17, 30, 188
hamartoma 21, 157, 190
hemangioma 12, 200
hematoma 22, 54, 155, 191 – 192, 219, 222, 227
following biopsy 134 – 135
hematopoietic malignancies 160
hereditary breast cancer 50
hormonal therapy 51, 253
palliative therapy 51, 52 – 53
hormone replacement therapy (HRT) 43, 175, 186
hypermastia 12
hyperthelia 12

I

image quality figure (IQF) 66, 67
imaging chain 60 – 61
incidence 40 – 41
see also risk factors
infections 4, 213, 227
following biopsy 134 – 135
inflammation 4, 21 – 22, 175, 177, 213, 215
inflammatory carcinoma of the breast 4, 33
palliative therapy 51
intensifying screens 71 – 72
interval cancer 36, 245 – 249
intraductal carcinoma *see* ductal carcinoma in situ
invasive ductal carcinoma (IDC) 25 – 27, 28, 159, 214, 224, 252
invasive lobular carcinoma (ILC) 27 – 28, 160, 191, 195, 211, 214, 215, 252

K

keloid formation 220 – 222
keyhole sign 175

L

lactation 6, 12, 34 – 35, 168
infections 4, 21
lactiferous ducts 6, 7, 153
asymmetry 185
lateromedial view 116, 118
lifestyle factors 43 – 44
Linguini sign 175, 231
lipoma 21, 157, 188, 190, 210
lipomatosis 210
lobular carcinoma in situ (LCIS) 24 – 25
treatment 54
luminance 83 – 85
lumpectomy 219
lumps 2 – 3
lymphadenopathy 217
lymphatic leukemia 217
lymphatic system 10 – 12
lymph nodes 157, 190 – 191, 200, 217 – 219
axillary 217 – 219
enlarged 160, 168 – 169, 217, 230
intramammary 219
radiation of regional lymph nodes 48, 50
retrosternal 150, 219
see also axillary node dissection
lymphoma 167, 189
non-Hodgkin 160, 217

M

magnetic resonance imaging (MRI) 170 – 179, 225, 257
breast implants and 230
magnification mammography 118 – 119, 126 – 129, 257
male patients 252 – 254
breast cancer 252 – 253, 254
gynecomastia 252, 254
mammography 253 – 254
positioning 121
malignant seeding, following biopsy 135
mammary gland 7 – 8
mammography 60 – 91, 163, 256 – 257
automatic exposure control (AEC) 80 – 83, 100
breast implants and 121, 230
computer-aided reading 90 – 91
contrast 61, 62, 64 – 70, 74 – 76, 80
density of the mammogram 73 – 74, 78 – 80
digital image receptors 85 – 90
dose 66, 68 – 69
films 71 – 73, 75 – 76, 256 – 257
processing 72 – 73
image blur 76 – 77, 80
image quality 62 – 63
image quality figure (IQF) 66, 67
imaging chain 60 – 61
magnification mammography 118 – 119, 126 – 129, 257
male breast 253 – 254

noise 62, 65 – 66, 77 – 78, 80
quality assurance 83 – 84, 93 – 94, 98 – 99, 122
medical quality criteria 63 – 64, 93
radiation exposure 92 – 93
reproducibility 80
sharpness 61, 64, 70 – 71
viewbox/viewing conditions 83 – 85, 184 – 186
see also projections; screening
Mammotome 137
masking 85, 184
mastalgia 2
mastectomy 49 – 51, 253
palliative therapy 51
postoperative radiation 50
recurrence after 34
mastitis 4, 21, 168, 215, 222
mastitis obliterans 22
mastitis puerperalis 21
periductal mastitis 22
plasma cell mastitis 22, 200
retention mastitis 21
retromammillar nonpuerperal mastitis 168
mastopathy 158, 167, 172, 191, 214, 239
mediolateral oblique (MLO) view 100 – 101, 109 – 115
mediolateral view 116, 117
melanoma 160
menarche 12, 42
menopause 12, 42
menstrual cycle 2, 6, 9, 12, 175
metastases 34, 45, 50 – 52, 150, 160, 189, 217, 238, 254
bone metastases 52, 53, 253
localization of 52
palliative treatment 51 – 52
microcalcifications *see* calcifications
micromastia 12
milk of calcium 17, 199, 201
modulation transfer function (MTF) 64, 70, 77
Mondor disease 4, 22, 158, 213, 215
mortality rates 41, 244
multicentricity 33
multifocality 33
myoepitheliocytes 7
myoepithelioma 21

N

neurofibroma 215
nipple
discharge 3, 32, 147, 252
eczema (Paget disease) 3, 4, 32
edema 4
retraction 3, 4, 28, 222, 252
supernumerary 12
nodular lesions 187 – 193
with ill-defined margin 191 – 192
with well-defined margin 188 – 191
nodularity 2
noise 62, 65 – 66, 77 – 78, 80
nutritional factors 43

O

obesity 43
oil cysts 155, 190, 191 – 192, 222, 224
oral contraceptives 43
organochlorines 44

P

Paget disease 3, 4, 32, 215
pain relief 53
palliative therapy 45, 51 – 53, 253
papilloma 172, 174, 175, 190, 200
intracystic 190
intraductal 20 – 21, 147, 157 – 158, 190
juvenile multiple 21
papillomatosis 18, 20, 155, 190
juvenile 21
parenchymal pattern 9
patient self-help groups 55
peau d'orange 4, 33, 215
phyllodes tumor 3, 20, 157, 167, 188, 189, 210
plasma cell mastitis 22, 200
pneumocystography 148 – 149, 188
polymastia 12
positioning 98, 100 – 101, 122, 184
axillary view 121
breast implants and 121
caudocranial view 121
computed tomography (CT) 150
craniocaudal (CC) view 101
extended CC view (Cleopatra view) 120
lateromedial view 118
male patients 121
mediolateral oblique (MLO) view 109 – 110
mediolateral view 117
MR mammography 170
recumbent patients 121
tangential view 121
pregnancy 6, 12, 34 – 35, 167
prevention 44 – 45, 236
projections 100 – 121
axillary view 121
caudocranial view 121
craniocaudal (CC) view 101 – 108
extended CC view (Cleopatra view) 120
lateromedial view 116, 118
magnification views 118 – 119
mediolateral oblique (MLO) view 100 – 101, 109 – 115
mediolateral view 116, 117
recumbent patients 121
spot views 118 – 119
tangential view 121
pseudo-lesions 191
psoriasis 215, 217

Q

quadrantectomy 219
quality assurance and control 55, 63 – 64, 83 – 84, 93 – 94, 98 – 99, 122

R

radial scar 19, 186, 194, 212 – 213, 214
radiation exposure 44, 92 – 93, 244
radiography *see* mammography
radiotherapy 186, 215, 224
ductal carcinoma in situ 53 – 54
following mastectomy 50
in breast conservation therapy 46 – 49
palliative therapy 51, 52
raloxifene 45
resolution 60 – 62, 70 – 71
rheumatoid arthritis 217
risk factors 41 – 44

S

sarcoma 9, 160, 188
scar
radial 19, 186, 194, 212 – 213
surgical 213, 214, 222, 224 – 225
scirrhus 193
screening 44, 80, 90, 236 – 250, 257
cost-benefit and cost-effectiveness 244
European guidelines 237 – 238
for metastases 45
interpretation 243
operational models 242
quality assurance 83 – 84
theoretical basis 238 – 241
self-help groups 55
sentinal node biopsy 46
seroma 155, 219, 222, 227
sharpness 61, 64, 70 – 71
signal-to-noise ratio (SNR) 65 – 66, 67
silicone implants *see* breast implants
skin 3, 9, 185, 215
asymmetry 185
edema 3, 4, 33, 215, 220 – 222
erythema 3
retraction 28, 215, 220, 222
thickening 4, 28, 215, 220 – 222, 224
smoking 43
sonographic guidance 137 – 138, 144
sonography 151 – 169, 230, 257
benign lesions 156 – 158
evaluation of 167 – 168
breast implants and 230
contribution of 168 – 169
cystic lesions 155 – 156
Doppler sonography 160 – 162
imaging technique 151
indications for 162 – 167
lesion characteristics 153 – 155
malignant lesions 158 – 160
technical considerations 151
spicules 193, 194, 209
spot views 118 – 119
staging 45
stellate lesions 193 – 198, 209, 211, 245
stereotactic guidance 138 – 142, 144 – 145, 257
symmetry 184 – 185

T

tail of Spence 101
tamoxifen 45, 50 – 51, 53
tangential view 121

TDLU (terminal ductal lobular unit) 7 – 9, 188
teacup phenomenon 17, 199
team of experts 54
teardrop sign 175
technician, role of 98 – 99
tent sign 185, 186, 213
tentacles 193
thermography 180
thickened skin syndrome of the breast 215
thrombophlebitis 4, 22, 158, 213
TMN classification 45
TRAM flap 225, 227
transducers 151
transillumination 180
treatment 45 – 55, 236
  curative therapy 45 – 51
  ductal carcinoma in situ 53 – 54
  interdisciplinary cooperation 54 – 55
  lobular carcinoma in situ 54
  older women 54
  palliative therapy 45, 51 – 53, 253
  staging 45
  see also breast conservation therapy; radiotherapy
tuberculosis 200, 213, 214, 217

U

ultrasound intensity 151
  see also sonography

V

vascularity 160 – 162
vasovagal reactions 135
veins 10 – 11, 185
viewbox 83 – 85, 184
von Recklinghausen disease 215

W

wart 185